* CervoMed Inc CRVO.OQ CRVO.O is expected to report
resultson
August 6 (estimated) for the period ending June 30 2024
* The Boston Massachusetts-based company is expected to
report
revenue of $2.2 million, according to the mean estimate from 4
analysts, based on LSEG data.
* LSEG's mean analyst estimate for CervoMed Inc is for a
loss
of 31 cents per share.
* The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 4 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell."
* The mean earnings estimate of analysts was unchanged in
the last
three months.
* Wall Street's median 12-month price target for CervoMed
Inc is
$63.00, above its last closing price of $10.63.
Previous quarterly performance (using preferred earnings measure
in US dollars).
QUARTER STARMINESM LSEG IBES ACTUAL BEAT, SURPRI
ENDING ARTESTIMAT ESTIMATE MET, SE %
E® MISSED
Mar. 31 2024 -0.39 -0.39 -0.41 Missed -5.1
Dec. 31 2024 -0.29 -0.29 -0.38 Missed -31
Sep. 30 2023 -0.95 -0.95 -0.70 Beat 26.3
Jan. 1 0001 -2.97 -3.09 -2.05 Beat
Jan. 1 0001 -3.06 -3.06 -3.09 Missed -1
This summary was machine generated August 3 at 00:35 GMT. All
figures in US dollars unless otherwise stated. (For questions
concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com)